

Method for identifying compounds modulating sister chromatid separation

The present application claims the benefit, under 35 U.S.C. § 119, of the earlier filing dates of European Patent Application No. EP 01 101 252.3, filed January 19, 2001, and U.S. Provisional Application No. 60/297,440, filed June 13, 2001. The contents of each of these applications are entirely incorporated herein by reference.

The invention relates to compounds influencing mitosis and meiosis in eukaryotic cells and methods for identifying such compounds. In particular, the invention largely relates to the treatment and prevention of human conditions by modulating sister chromatid segregation.

A key prerequisite for the successful division of one cell into two is the duplication and subsequent segregation of the cellular genome into the two forming daughter cells. Duplication of the genome by DNA replication occurs during synthesis (S) phase of the cell cycle, whereas segregation of the duplicated DNA takes place much later during anaphase of mitosis. During S phase, replicated DNA molecules remain physically attached to each other, a phenomenon called cohesion, until they are separated in anaphase. At the beginning of mitosis, the cellular DNA is condensed into chromosomes, in which each of the two replicated DNA molecules are microscopically visible as sister chromatids. To allow the segregation of sister chromatids to the forming daughter cells in anaphase, the cohesion that is holding sisters together has to be dissolved. This process is mediated by a protease, called separin or separase, that is cleaving a complex of chromosomal cohesion proteins (the cohesin complex) that is required to hold sister chromatids together. This cleavage reaction liberates

sisters from each other so that they can be pulled towards opposite poles of the dividing cells by the spindle apparatus (reviewed by Nasmyth et al., 2000).

Inhibition of cohesin cleavage by separase in experimental systems such as budding yeast or human cultured cells inhibits sister chromatid separation and thus prevents the formation of viable daughter cells (Uhlmann et al., 1999; Uhlmann et al., 2000; Hauf et al., 2001).

WO 00/48627 suggests a method for identifying compounds which exert their effect by directly modulating, in particular by inhibiting separase's proteolytic activity, i.e. by being protease inhibitors specific for separase. (In the following, if not otherwise stated, "separase" stands for "human separase".)

The screening method for identifying compounds that have the ability of modulating sister chromatid separation in plant or animal cells as described in WO00/48627 comprises incubating separase, in the presence of the substrate(s) for its proteolytic activity and optionally its co-factor(s), with test compounds and determining the modulating effect of the test compounds on the proteolytic activity of the separase.

It was an object of the invention to gain further insight into the mechanism of sister chromatid separation, in particular to elucidate the mechanism by which separase exerts its proteolytic activity, which has been shown to be involved in this process. The mechanism of separase activation provides the basis for developing improved enzymatic assays to identify modulators, in particular inhibitors of separase, in order to provide drugs that exert their effect by modulating, in particular inhibiting, sister chromatid segregation.

The identification of small molecule inhibitors of separase requires enzyme assays in which the protease activity of separase can be directly measured. Preferably, such assays are adaptable to high throughput formats so that large libraries of chemical compounds can be tested for their ability to

inhibit separase. The previously reported experiments demonstrating that separase is associated with a protease activity were performed with separase isolated in small scale by immunoprecipitation or affinity chromatography from either yeast or human cells (Uhlmann et al., 2000; Waizenegger et al., 2000). Along these lines, WO00/48627 suggests to use full-length separase, preferably in recombinant form, for performing protease assays.

The protease activity of separase is tightly regulated during the cell cycle, ensuring that the ability of separase to cleave cohesin and thereby to dissolve sister chromatid cohesion is not activated before the transition from metaphase to anaphase. Work in budding yeast and human cells has shown that prior to anaphase separase is inhibited by a protein called securin (Ciosk et al., 1998; Uhlmann et al., 1999; Waizenegger et al., 2000). Securin binds to separase until securin is ubiquitinated by the anaphase-promoting complex and subsequently degraded by the 26S proteasome shortly before the onset of anaphase. The destruction of securin is thought to activate separase. In human cells, separase itself is cleaved at the same time as securin is destroyed, resulting in at least two C-terminal cleavage products called p55 and p60 (Waizenegger et al., 2000). These results suggest that the activity of separase is controlled by both securin destruction and separase cleavage. It is not known however and cannot be concluded from these results, which form of the separase, i.e. the full-length form or the cleavage products of separase, represent the active form of the protease or whether and in which way securin has a potential to contribute to the activation of separase.

To establish a separase protease assay suitable for high throughput format it is essential to know which form of separase represents the active enzyme and how the active form of separase can be obtained.

The present invention provides the first evidence that the cleaved forms of separase represent the active protease and that N- and C-terminal

cleavage products of separase remain physically associated. The present invention further provides evidence that securin inhibits separase by directly binding to it. Securin binding to separase could either directly block the access of substrates to the active site of separase or it could keep separase in a conformation in which its active site is not accessible to substrates. The present invention further provides evidence that it is the autocatalytic reaction, i.e. the reaction in which separase cleaves itself, which is responsible for the cleavage of separase into its active form. Finally, the present invention shows that active forms of tagged recombinant full-length separase can be obtained and that fluorogenic peptide substrates are useful to measure the protease activity of separase.

It was previously reported that active human separase can be obtained by immunoprecipitating separase from human cell extracts (Waizenegger et al., 2000). Briefly, antibodies specific for the C-terminus of separase coupled to beads are incubated in lysates obtained from human cultured cells (for example of the line HeLa) which have previously been arrested in mitosis by treatment with microtubule poisons such as nocodazole. After removal of the cell lysate the antibody beads with bound separase are incubated in mitotic *Xenopus laevis* egg extracts which are able to ubiquitinate and degrade the securin protein which is bound to separase when it is immunoprecipitated from mitotic human cell lysates. During the incubation in mitotic *Xenopus* extracts the majority of securin is degraded, but in addition a major portion of human separase is also cleaved. After washing away the *Xenopus* egg extracts the antibody beads with bound separase are incubated with either purified cohesin complexes or with recombinant SCC1, which is the subunit of the cohesin complex that is cleaved by separase. The activity of separase is then monitored by analyzing the cleavage of SCC1, which can be analyzed by SDS gel electrophoresis and subsequent immunoblotting with antibodies to SCC1. If recombinant radioactively labeled SCC1 is used the gels can also be analyzed by autoradiography or Phosphorimaging.

In the experiments of the invention (Example 1), it was found that securin is able to bind to separase. It was shown that securin can bind to the cleaved form of separase as well as to the full-length separase. It was found that securin binding to separase inhibits the protease activity of separase (Fig. 1).

To further study the mechanism of separase activation it was tested if two different peptide inhibitors developed to inhibit separase from budding yeast are able to inhibit the protease activity of human separase. It was found that the concentration of these peptide derivatives required to inhibit human separase was similar to the concentration needed to inhibit separase from budding yeast (compare Fig. 2, upper panel and WO 00/48627, Uhlmann et al., 2000). It was further observed that the formation of the p55 cleavage product of human separase was largely inhibited by both peptides at the same concentration at which the ability of separase to cleave SCC1 was inhibited. The obtained results suggest that separase activity itself is required for separase cleavage, i.e. that separase cleavage occurs autocatalytically.

Peptide inhibitors developed on the basis of the cleavage recognition site of human SCC1, "DREIMR", were also able to inhibit separase at a similar concentration as the above mentioned peptide inhibitors (Fig. 3).

It was further tested which form of separase represents the active protease. It was found that the peptide inhibitor Bio-SVEQGR-amk bound exclusively to the cleaved forms of human separase when the peptide derivative was added to separase after its activation in mitotic *Xenopus* extracts. This observation shows that the active site of separase is accessible to Bio-SVEQGR-amk in the cleaved, but not in the residual amount of full-length separase to which securin is still bound (Fig. 4). These results suggest that the cleaved forms of separase represent active forms of the protease.

The obtained results also suggest that the full-length form of separase is also transiently active, presumably once its bound inhibitor securin has been destroyed, but that this form is normally labile because it is further processed into the cleaved forms by autocleavage.

It was shown that securin inhibits separase by directly or indirectly blocking the access of substrates to the active site of separase (Fig 4D). It was further shown directly that separase cleavage can occur autocatalytically in trans and two cleavage sites in human separase were mapped (Fig. 8).

To test if the N- and C-terminal fragments of separase remain non-covalently associated after cleavage, tagged forms of separase were generated. During the course of these experiments it was recognized that recombinant separase expressed from the published cDNA sequence (KIAA 0165) was not the full length human enzyme but instead a fragment lacking the N-terminus of separase. The 5'-end of the human separase cDNA that encodes the missing N-terminus was therefore cloned. Subsequently, N-terminally FLAG-tagged full-length separase was transiently expressed in HeLa cells and isolated by immunoprecipitation with an anti-FLAG antibody. The immunoprecipitates were incubated in mitotic *Xenopus* egg extracts to allow securin destruction and separase cleavage. The finding that both C- and N-terminal separase fragments could be detected in the immunoprecipitates, suggested that the N- and C-terminal separase fragments remain associated after cleavage (Fig. 6).

Together, the obtained results suggest the model for the activation of human separase that is shown in Figure 7. According to this model, full-length separase (p200) is associated with securin and represent the inactive state of the protease. Upon proteolysis of securin a labile full-length form of separase exists. The cleaved forms of separase stay physically associated with the N-terminal fragment(s) and represent the stable, active enzyme.

The findings of the present invention show that protease assays for identifying separase inhibitors can be based on an active form of human separase, which is present in the cleaved forms of separase. These forms have the advantage to be more stable than the complete separase molecule and are thus expected to be better suitable for being employed in a high throughput format assay.

In order to obtain one or more active, stable forms of separase, the following steps can be taken:

Recombinant forms of the p55 and p60 cleavage products (Waizenegger et al., 2000), or potential other active cleavage products of separase, are produced in suitable expression systems, purified and tested for their ability to cleave SCC1, or a fragment thereof that contains the separase cleavage site, in vitro. Standard expression systems such as *E. coli*, budding yeast, Baculovirus infected Sf9 and Hi5 insect cells and transfected mammalian, e.g. human cells can be used. For purification, standard biochemical protocols can be used, e.g. those described in WO00/48627 for obtaining separase.

If p55 or p60 (or another, natural or synthetic, C-terminal fragment of human separase) alone or in combination with another fragment is sufficient for separase activity, the respective fragment (or a combination of fragments) can be employed in the protease assay (as described in WO00/48627) as a substitute for the full-length separase molecule.

Since the N- and C-terminal cleavage products of separase remain associated with each other (see above, Figure 6) it is also possible that both the N- and the corresponding C-terminal fragments will be required to obtain active recombinant separase. The two or more fragments can either be expressed individually, purified and then mixed together, or they can be co-expressed in expression systems as listed above, and the obtained complexes containing both N- and C-terminal fragments are purified. All of

these forms, e.g. all combinations of C-terminal and corresponding N-terminal fragments, will then be tested for their ability to cleave SCC1 in vitro. If any of the complexes described above yields human separase activity, the respective complex of separase fragments can be employed in the proteolytic assay in the same manner as a C-terminal fragment by itself, as described above.

If the above-described approach using complexes comprising various separase fragments does not exhibit human separase activity, full-length human separase is expressed in expression systems as listed above, the recombinant protein is isolated and activated, e.g. by incubation in mitotic *Xenopus* egg extracts, to induce its activation by cleavage.

In parallel, complexes of separase and securin can be generated to investigate whether the binding of securin to separase may not only inhibit separase but may also be required for its subsequent activation. To test this possibility, either recombinant securin is added to recombinant separase after their individual expression and purification, or securin and separase are co-expressed in expression systems as above. All forms of separase, i. e. full-length separase, separase fragments or combinations of fragments, with and without transiently bound securin, are tested for their ability to cleave SCC1 in vitro after incubation of the different forms of separase in mitotic *Xenopus* extracts.

In the case that these experiments result in the finding that securin is required for human separase activity, the assay is performed by employing the respective form of separase (fragment(s)) in combination with securin. The separase (fragment) is activated in the presence of securin in cell extracts, e.g. *Xenopus laevis* cell extracts. Preferably, as for the other assay components, securin, or a fragment thereof that proves to be sufficient for activation of separase (if not stated otherwise, "securin" also stands for an active fragment thereof) is employed in recombinant form, based on the cDNA sequence (Lee et al., 1999; Zhang et al, 1999). In order

to obtain a protein complex for the assay, the separase (fragment) and securin can either be expressed and purified separately and then combined or they can be co-expressed and co-purified; as described above.

The results of Figure 6 shows that the latter approach is feasible. Flag-tagged separase was coexpressed with myc-tagged securin in HeLa cells. Coexpression with securin lead to a higher yield of separase. Mitotically activated separase immunoprecipitates were able to cleave SCC1.

Once the active form(s) of human separase have been obtained by one or more of the methods described above, synthetic peptide substrates for separase are designed and synthesized that allow the simple detection of protease activity in high throughput format, e.g. by fluorogenic methods. The proteolytic assays suitable for this purpose have been described in WO00/48627. By way of example, substrate peptides containing the separase recognition sequence (see WO00/48627) that carry a C-terminal fluorophore such as a 7-amino-4-methyl-coumarin group (AMC) are synthesized by standard methods. The cleavage of AMC (or other fluorophore groups used) results in a rise in fluorescence which can be measured fluorometrically. In an experiment of the present invention, the activity of mitotically activated immunoprecipitates of separase (Waizenegger et al., 2000) was measured fluorometrically by using AMC-coupled peptides based on the cleavage recognition sites of human separase, "SFEILR". The result of this experiment provides the basis for the development of a screening assay for identifying separase inhibitors. For conducting this assay in the high throughput mode, compounds, e.g. from chemical or natural product libraries, can be tested for their ability to inhibit the cleavage of fluorogenic peptide substrates by the active form(s) of human separase, which is preferably employed in the screen in recombinant form.

Similarly, the approaches as described above can be used to determine the active forms of separase from other eukaryotic organisms, to generate

these forms as recombinant active proteins and to establish screening method for identifying inhibitors of these enzymes.

The present invention relates to method for identifying a compound that has the ability of modulating sister chromatid separation by inhibiting the proteolytic

activity of separase, characterized in that an active separase in the form of

- a) one or more separase fragment(s), optionally upon activation in the presence of securin, or
- b) full-length separase upon activation in the presence of securin,

is incubated in the presence of a separase substrate, with a test compound and that the modulating effect of the test compounds on the proteolytic activity of the separase is determined.

Any variation of the proteolytic screening assay method of the invention, e.g. carried out with one or more separase fragments, in the presence or absence of securin, can be carried out according to standard methods, in particular as described in WO 00/48627:

Various assay methods for identifying protease inhibitors that are useful in the present invention and are amenable to automation in a high-throughput format have been described, e.g. the radiometric method described by Cerretani et al., 1999, for hepatitis C virus NS3 protease, the method based on fluorescence quenching described by Ambrose et al., 1998, or by Taliani et al., 1996, the microtiter colorimetric assay for the HIV-1 protease described by Stebbins and Deboucq, 1997, the fluorescence polarization assay described by Levine et al., 1997 (reviewed by Jolley, 1996), the method using immobilized peptide substrates described by Singh et al., 1996, the assay used for studying the inhibition of cathepsin G, using biotinylated and cysteine-modified peptides described by Brown et al., 1994. A further example for a suitable assay is based on the

phenomenon of fluorescence resonance energy transfer (FRET), as described by Gershkovich et al., 1996 or by Matayoshi et al., 1990. Additional examples for assays that may be used in the present invention for a high-throughput screening method to identify inhibitors of separase activity were described by Gray et al., 1994, Murray et al., 1993, Sarubbi et al., 1991.

Fluorescent or radioactive labels and the other reagents for carrying out the enzymatic reaction on a high-throughput scale are commercially available and can be employed according to supplier's instructions (e.g. Molecular Probes, Wallac). The specific assay design depends on various parameters, e.g. on the size of the substrate used. In the case of using a short peptide, the fluorescence quenching or the fluorescence resonance energy transfer methods are preferred examples for suitable assay technologies.

The fluorescence quenching (Resonance Energy Transfer „RET“) assay relies on synthetic substrates which are capable of direct, continuous signal generation that is proportional to the extent of substrate hydrolysis. The substrate peptide carries a fluorescent donor near one end and an acceptor near the other end. The fluorescence of the substrate is initially quenched by intramolecular RET between donor and acceptor. Upon cleavage of the substrate by the protease the cleavage products are released from RET quenching and the a fluorescence proportional to the amount of cleaved substrate can be detected. In Example 9, this type of assay is exemplified by use of AMC; which serves as a donor fluorophore and in the case of the separase-specific peptide substrates the amino acid bonds of the peptides function as acceptor chromophores.

An assay of this type may be also carried out as follows: the solution of the labeled substrate (e.g. the peptide labeled with 4-[(4'-dimethylamino)phenyl]azo]benzoic acid (DABCYL) at the one end and with 5-[(2'-aminoethyl)amino]naphtalenesulfonic acid (EDANS) at the other end or labeled with benzyloxycarbonyl at the one end and with 4-

aminomethylcoumarin at the other end) in assay buffer is pipetted into each well of black 96-well microtiter plates. After addition of the test substances in the defined concentration, the separase activity containing solution is added to the wells. After incubation under conditions and for a period of time sufficient for the proteolytic cleavage reaction, e.g. for 1 hour at room temperature, the fluorescence is measured in a fluorometer at the excitation wavelength, e.g. at 340 nm, and at the emission wavelength, e.g. at 485 nm.

In the case of using the FRET assay, labeling pairs that are suitable for the method of the invention are commercially available, e.g. Europium (Eu) and Allophycocyanin (APC), Eu and Cy5, Eu and PE (Wallac, Turku, Finland).

The compounds identified in the above methods have the ability to interfere with sister chromatid separation by modulating the proteolytic activity of separase.

The present invention also relates to compounds which act as inhibitors of separase for use in human therapy, in particular cancer therapy.

In a further aspect, the invention relates to a pharmaceutical composition which contains, as the active ingredient, one or more compounds which interfere with or modulate sister chromatid separation by inhibiting separase activity.

In a preferred embodiment, the invention comprises pharmaceutically active compounds and their use in therapy, which are small chemical molecules that have been identified as separase inhibitors in the screening method of the invention.

As an alternative to identifying small molecules in a screening method, separase inhibitors can be obtained starting from the recombinant active separase. In this approach, synthetic peptide derivatives, exemplified by derivatives of SVEQGR, DREIMR, SFEILR or EWELLR (e.g. Bio-SVEQGR-

amk) can be used as the structural basis to develop peptidomimetic molecules that inhibit separase. For inhibitors of human separase, the cleavage sequence of human SCC1 or human separase can preferably be used. The assays described above using recombinant active separase and peptide substrates, e.g. fluorogenic peptides, can be used to optimize such compounds.

Inhibitors of human separase activity identified in the screening methods of the invention or based on rational inhibitor design can be used as cytotoxic therapeutics for the treatment of diseases that are caused by uncontrolled cell proliferation, such as cancers, leukaemias, or cardiac restenosis. Species specific inhibitors of separase from eukaryotic pathogenic microorganisms can be used to treat infectious diseases caused by such microorganisms, for example infections caused by pathogenic fungi or diseases caused by parasites such as *Leishmania* species.

To address how separase inhibition affects cell cycle progression, RNA interference experiments can be used to knock out separase expression in human cultured cells, according to known methods, as described, e.g. by Elbashir et al, 2001.

Influencing the process of sister chromatid separation may be also beneficial in preventing birth defects caused by missegregation of chromosomes in human meioses. For example, since cases of human aneuploidy such as Down's syndrome may be caused by premature separation of sister chromatids (Griffin, 1996), the use of a drug that inhibits separase activity might be able to reduce precocious sister separation and thereby the incidence of aneuploidy in human fetuses.

Thus, in a further aspect, the invention relates to separase inhibitors for the prevention of birth defects caused by missegregation of chromosomes in human meioses.

The efficacy of compounds identified as separase inhibitors in the method of the invention, can be tested for *in vivo* efficacy either on yeast cells or in mammalian cells. Effective compounds should block (or at least in some way interfere with) sister chromatid separation, which can be measured, e.g. by using CenV-GFP in yeast, as described by Ciosk et al., 1998, or standard cytological techniques in mammalian cells. Compounds effective in tumor therapy should be either cytostatic or cytotoxic. Substances whose potential for therapeutic use has been confirmed in such secondary screens can be further tested for their effect on tumor cells.

To test the inhibition of tumor cell proliferation, primary human tumor cells are incubated with the compound identified in the screen and the inhibition of tumor cell proliferation is tested by conventional methods, e.g. bromo-desoxy-uridine or ^3H incorporation. Compounds that exhibit an anti-proliferative effect in these assays may be further tested in tumor animal models and used for the therapy of tumors.

Toxicity and therapeutic efficacy of the compounds identified as drug candidates by the method of the invention can be determined by standard pharmaceutical procedures, which include conducting cell culture and animal experiments to determine the IC_{50} , LD_{50} , the ED_{50} . The data obtained are used for determining the human dose range, which will also depend on the dosage form (tablets, capsules, aerosol sprays, ampules, etc.) and the administration route (oral, buccal, nasal, paterental or rectal). A pharmaceutical composition containing the compound as the active ingredient can be formulated in conventional manner using one or more physiologically active carriers and excipients. Methods for making such formulations can be found in manuals, e.g. "Remington Pharmaceutical Sciences".

Separase inhibitors may also be useful in applications which aim at the deliberate polyploidisation of plant cells for crop development. In yeast, it has been shown that inhibition of separase activity prevents chromosome

separation without blocking cell cycle progression and therefore gives rise to cells with increased ploidy. Inhibitors that block separase's protease activity could therefore be used to increase the ploidy of any eukaryotic cell, including all plant cells. Increasing the ploidy of plant cells is useful for 1) producing larger plants, 2) for increasing the ploidy of breeding stocks, and 3) for generating fertile hybrids.

Therefore, the present invention relates, in a further aspect, to separase inhibitors for the treatment of plant cells for increasing their ploidy.

To identify separase inhibitors that are useful for the above-mentioned agricultural purposes, the screening method of the invention can be easily adapted by employing plant components, i.e. a plant separase and a plant homolog of SCC1. Sequence homologs of plant separase and SCC1 are present in databases, e.g. of the *Arabidopsis thaliana* genome.

Separase inhibitors which impair sister chromatid separation may also be used in cytological analyses of chromosomes, for example, in medical diagnoses of chromosome structure.

Brief description of the Figures:

Fig. 1: Securin acts as an inhibitor for separase

Fig. 2: Yeast peptides inhibit proteolytic activity of human separase in similar concentration as they inhibit yeast separase and influence the processing of human separase

Fig.3: Human peptides inhibit proteolytic activity of human separase in a similar concentration as the yeast peptides do

Fig. 4: Addition of yeast peptides at different stages during the activation of separase suggests that the cleaved forms are the active forms of separase and securin binding blocks access of peptide substrates to the active site of separase

Fig. 5: Mitotically activated separase has autocatalytic activity

Fig. 6: N- and C-terminal cleavage products of human separase stay associated after mitotic cleavage and ectopically expressed separase is able to cleave human SCC1

Fig. 7: Working model for the activation of human separase

Fig. 8: Mapping of the cleavage sites in human separase

Fig. 9: A Principle of fluorogenic separase inhibitor screening assay

B: Processing of a separase peptide substrate by trypsin

Fig. 10: In vitro assay using activated separase bound to microbeads

Fig. 11: Transcleavage separase screening assay showing inhibiting effect of small molecular compounds

Material and methods:

SCC1 in vitro cleavage assay

Inactive human separase (separase) immunoprecipitates were activated in mitotic *Xenopus* egg extracts (for details see Waizenegger et al., 2000). 30 microliter beads were incubated with 40 µg bacterially expressed wildtype securin, destruction box deleted form of securin (Gmachl et al., 2000) or BSA diluted in XB + 1 mM DTT for 40 min at RT. Subsequently the beads were washed with XB + 1 mM DTT and with TBS + 0.5 M NaCl + 1 mM DTT + 0.5% TWEEN20, followed by one wash with XB + 1mM DTT. To control the rebinding of securin an aliquot of 5 µl was taken per assay and subsequently analysed by immunoblotting with antibodies against separase and securin.

The beads were used for the SCC1 in vitro cleavage assay: 20 µl beads were mixed with 30 µl of the following SCC1 in vitro translation mix (SCC1myc IVT + 1 µl PLK-GST + 0.3 µl 1 M MgCl₂, 0.3 µl 100 mM ATP, 0.12 µl 250 mM EGTA, 13.78 µl XB + 1mM DTT) and incubated at 22° C and 1200 rpm. 5 µl were taken per time point, the reaction was stopped by addition of SDS loading buffer. Samples were analyzed by immunoblotting with mouse monoclonal antibodies against myc (9E10).

Modifications:

A. Mitotically activated separase immunoprecipitates were preincubated with yeast peptides (Uhlmann et al., 2000) before they were used in the SCC1-cleavage assay. Biotin-SVEQGR-amk or Biotin-SVEQGR-cmk were used at different concentration (0.1, 1, 10, 100, 1000 µM in XB + 0.5 mM DTT). Separase immunoprecipitates were incubated for 10 minutes, 22° C and 1200 rpm. The SCC1 in vitro cleavage assay was performed after washing once with XB + 0.5 mM DTT (see above). Human peptides, Biotin-

DREIMR-amk or DREIMR-amk, were diluted and used as above described for the yeast peptides.

B. Separase immunoprecipitates were incubated with 100 μ M Biotin-SVEQGR-amk or with DMSO prior mitotic activation. Incubation for 10 minutes, 22° C and 1000 rpm. After washing twice in XB + 1mM DTT the activation was performed in mitotic *Xenopus* egg extracts.

Interphase *Xenopus* egg extracts were driven into mitosis in the presence of 1 mM Biotin-SVEQGR-amk or DMSO. Those mitotic *Xenopus* egg extracts were used to activate a batch of separase immunoprecipitates.

Biotin labeled peptides were detected via immunoblotting according to Faleiro et al., 1997.

C. Mitotically activated separase immunoprecipitates were preincubated with either 8 μ g recombinant securin or with 8 μ g of a C-terminal truncated version of cyclinB in 100 μ l XB+ 1 mM DTT for 30 min at 22° C and 1250 rpm. Subsequently the beads were washed twice with TBS + 0.5 M NaCl + 1 mM DTT + 0.5 % Tween 20 and twice with XB + 1 mM DTT. Thereafter beads were incubated with 100 μ l of 100 μ M Bio-DREIMR-amk in XB + 1 mM DTT. After 10 min incubation at 22°C and 1250 rpm beads were again washed and analyzed by immunoblotting.

D. A separase construct tagged with one myc epitope at its C-terminus was in vitro transcribed and translated and then used as a substrate for separase bound to beads. The reaction mix was supplemented as described above for the SCC1 cleavage assay. The myc tag allowed the discrimination between separase as a substrate and as an enzyme.

Example 1

Securin acts as an inhibitor for separase

To test if securin inhibits separase by directly binding to it and if it is still able to bind and inhibit the cleaved form of separase human securin was expressed in *E. coli* and purified. When the recombinant securin was added to separase that had been isolated by immunoprecipitation and had been activated in mitotic *Xenopus* extracts as above it was observed that securin was able to bind to separase (Figure 1A). Importantly, the amount of securin that bound to separase was at least as high as the amount of securin that had been bound to separase originally before securin was degraded by incubating the separase immunoprecipitates in mitotic *Xenopus* extracts, although the majority of separase had been cleaved during the incubation in the *Xenopus* extract. This result shows that securin can bind to the cleaved form of separase as well as to the full-length separase.

When the cleaved form of separase to which recombinant securin had been bound was incubated with recombinant SCC1, no cleavage of SCC1 was detected (Figure 1B), demonstrating that recombinant securin is able to inhibit the protease activity of separase by directly binding to it. Because the majority of separase used in this experiment was present in its cleaved form these observations suggest that it is the cleaved form of separase that is the active protease which cleaves SCC1, unless it is inhibited by the rebinding of securin. Identical results were obtained with two different forms of securin, the wildtype protein (WT-securin) and a form that can not be destroyed by ubiquitin-dependent proteolysis (DB-securin; Figure 1A and B).

Fig. 1A: Separase immunoprecipitates (separase IP) obtained from Nocodazole arrested HeLa cells and bound by antibodies against the C-terminus of separase coupled to beads were activated in mitotic *Xenopus* egg extracts (separase IP^{mitotic}). Mitotically activated separase immunoprecipitates were either incubated in buffer, wildtype securin, destruction box deleted securin or in BSA. Aliquots were taken and analysed by immunoblotting with antibodies against separase and securin.

Fig.1B: Activated separase immunoprecipitates which were either incubated with buffer, wildtype securin, destruction box deleted securin or BSA were incubated SCC1-myc reaction mix. Aliquots were taken at indicated timepoints and analysed by immunoblotting with antibodies against myc. Cleaved SCC1 is marked by arrows.

100 kDa
75 kDa
50 kDa
37 kDa
25 kDa
15 kDa
10 kDa
7.5 kDa
5 kDa
3.5 kDa
2.5 kDa
1.5 kDa
1 kDa
0.5 kDa
0.25 kDa
0.125 kDa
0.0625 kDa
0.03125 kDa
0.015625 kDa
0.0078125 kDa
0.00390625 kDa
0.001953125 kDa
0.0009765625 kDa
0.00048828125 kDa
0.000244140625 kDa
0.0001220703125 kDa
0.00006103515625 kDa
0.000030517578125 kDa
0.0000152587890625 kDa
0.00000762939453125 kDa
0.000003814697265625 kDa
0.0000019073486328125 kDa
0.00000095367431640625 kDa
0.000000476837158203125 kDa
0.0000002384185791015625 kDa
0.00000011920928955078125 kDa
0.000000059604644775390625 kDa
0.0000000298023223876953125 kDa
0.00000001490116119384765625 kDa
0.000000007450580596923828125 kDa
0.0000000037252902984619140625 kDa
0.00000000186264514923095703125 kDa
0.000000000931322574615478515625 kDa
0.0000000004656612873077392578125 kDa
0.00000000023283064365386962890625 kDa
0.000000000116415321826934814453125 kDa
0.0000000000582076609134674072265625 kDa
0.00000000002910383045673370361328125 kDa
0.000000000014551915228366851806640625 kDa
0.0000000000072759576141834259033203125 kDa
0.00000000000363797880709171295166015625 kDa
0.000000000001818989403545856475830078125 kDa
0.0000000000009094947017729282379150390625 kDa
0.00000000000045474735088646411895751953125 kDa
0.000000000000227373675443232059478759765625 kDa
0.0000000000001136868377216160297393798828125 kDa
0.00000000000005684341886080801486968994140625 kDa
0.000000000000028421709430404007434844970703125 kDa
0.0000000000000142108547152020037174224853515625 kDa
0.00000000000000710542735760100185871124267578125 kDa
0.000000000000003552713678800500929355621337890625 kDa
0.0000000000000017763568394002504646778106689453125 kDa
0.00000000000000088817841970012523233890533447265625 kDa
0.000000000000000444089209850062616169452667236328125 kDa
0.0000000000000002220446049250313080847263336181640625 kDa
0.00000000000000011102230246251565404236316680908203125 kDa
0.000000000000000055511151231257827021181583404541015625 kDa
0.0000000000000000277555756156289135105907917022705078125 kDa
0.00000000000000001387778780781445675529539585113525390625 kDa
0.000000000000000006938893903907228377647697925567626953125 kDa
0.0000000000000000034694469519536141888238489627838134765625 kDa
0.00000000000000000173472347597680709441192448139190673828125 kDa
0.000000000000000000867361737988403547205962240695953369140625 kDa
0.0000000000000000004336808689942017736029811203479766845703125 kDa
0.00000000000000000021684043449710088680149056017398834228515625 kDa
0.000000000000000000108420217248550443400745280086994171142578125 kDa
0.0000000000000000000542101086242752217003726400434970855712890625 kDa
0.00000000000000000002710505431213761085018632002174854278564453125 kDa
0.000000000000000000013552527156068805425093160010874271392822265625 kDa
0.0000000000000000000067762635780344027125465800054371356964111328125 kDa
0.00000000000000000000338813178901720135627329000271856784820556640625 kDa
0.000000000000000000001694065894508600678136645001359283924102783203125 kDa
0.0000000000000000000008470329472543003390683225006796419620513916015625 kDa
0.00000000000000000000042351647362715016953416125033982098102569580078125 kDa
0.000000000000000000000211758236813575084767080625169910490512847900390625 kDa
0.0000000000000000000001058791184067875423835403125849552452564239501953125 kDa
0.00000000000000000000005293955920339377119177015629247762262821197509765625 kDa
0.000000000000000000000026469779601696885595885078146238811314105987548828125 kDa
0.0000000000000000000000132348898008484427979425390731169056570529937744140625 kDa
0.00000000000000000000000661744490042422139897126953655845282852649688720703125 kDa
0.000000000000000000000003308722450212110699485634768279226414263248443603515625 kDa
0.0000000000000000000000016543612251060553497428173841396132071316242218017578125 kDa
0.00000000000000000000000082718061255302767487140869206980660356581211090087890625 kDa
0.000000000000000000000000413590306276513837435704346034903301782906055450439453125 kDa
0.0000000000000000000000002067951531382569187178521730174516508914530277252197265625 kDa
0.00000000000000000000000010339757656912845935892608650872582544572651386260986328125 kDa
0.000000000000000000000000051698788284564229679463043250437912722863256931304931640625 kDa
0.0000000000000000000000000258493941422821148397315216252189563614316284656524658203125 kDa
0.00000000000000000000000001292469707114105741986576081260947818071581423282623291015625 kDa
0.000000000000000000000000006462348535570528709932880406304739090357907116413116455078125 kDa
0.0000000000000000000000000032311742677852643549964402031523695451789535587035582275390625 kDa
0.00000000000000000000000000161558713389263217749822010157618477258947677935177911376953125 kDa
0.0000000000000000000000000008077935669463160887491100507880922386447383897383896878945625 kDa
0.00000000000000000000000000040389678347315804437455502539404611932236919486919484394728125 kDa
0.000000000000000000000000000201948391736579022187277512697023059661184597434597421973640625 kDa
0.0000000000000000000000000001009741958682895110936387563485115298305922987172987109368203125 kDa
0.00000000000000000000000000005048709793414475554681937817425576491529614935864935546841015625 kDa
0.000000000000000000000000000025243548967072377773409689087127882457648074679324677734205078125 kDa
0.0000000000000000000000000000126217744835361888867048445435639412288240373396623388671025390625 kDa
0.00000000000000000000000000000631088724176809444335242227178197061441201866983116943355126953125 kDa
0.000000000000000000000000000003155443620884047221676211135890985307206009334915584716775634765625 kDa
0.0000000000000000000000000000015777218104420236108381055679454926536030046674577923583878173828125 kDa
0.00000000000000000000000000000078886090522101180541905278397274632680150233372889617919390869140625 kDa
0.000000000000000000000000000000394430452610505902709526391986373163400751166864448089596954345703125 kDa
0.00000000000000000000000000000019721522630525295135476319599318658170037558343222404479847717236328125 kDa
0.000000000000000000000000000000098607613152626475677381597996593290850187791716112022399238586181640625 kDa
0.0000000000000000000000000000000493038065763132378386907989982966454250938958580560111996192930908203125 kDa
0.00000000000000000000000000000002465190328815661891934539949914832271254694792902800559980964654541015625 kDa
0.000000000000000000000000000000012325951644078309459672699749574161356273473964514002799904823272705078125 kDa
0.0000000000000000000000000000000061629758220391547298363498747870806781367369822570013999524116363525390625 kDa
0.00000000000000000000000000000000308148791101957736491817493739354033906836849112850069997620581817626953125 kDa
0.000000000000000000000000000000001540743955509788682459087468696770169534184245564250349988102909088134765625 kDa
0.0000000000000000000000000000000007703719777548943412295437343483850847670921227771251699940514545440673828125 kDa
0.00000000000000000000000000000000038518598887744717061477186717419254238354606138856258499702572727203369140625 kDa
0.000000000000000000000000000000000192592994438723585307385933587096271191773030694281292498512863636016845703125 kDa
0.0000000000000000000000000000000000962964972193617926536929667935481355958865153471406462492564318180084228515625 kDa
0.00000000000000000000000000000000004814824860968089632684648339677406779794325767357032312462821590900421142578125 kDa
0.000000000000000000000000000000000024074124304840448163423241698387033898971628836785161562314107954502105712890625 kDa
0.0000000000000000000000000000000000120370621524202240817116208491935169494858144183925807811570539772510528564453125 kDa
0.00000000000000000000000000000000000601853107621011204085581042459675847474290720919629039057852698862552642822265625 kDa
0.000000000000000000000000000000000003009265538105056020427905212298379237371453604598145195289263494312763214111328125 kDa
0.0000000000000000000000000000000000015046327690525280102139526061491896186857268022990725976446317471563816070556640625 kDa
0.00000000000000000000000000000000000075231638452626400510697760307459480934286340114953629882233187357819080352783203125 kDa
0.000000000000000000000000000000000000376158192263132002553488801537297404671431700574768149411165936789095401763916015625 kDa
0.0000000000000000000000000000000000001880790961315660012767444007686487023357158502873840747055829683945477008819580078125 kDa
0.00000000000000000000000000000000000009403954806578300063837220038432435116785792514369203735279148419727385044097900390625 kDa
0.000000000000000000000000000000000000047019774032891500319186100192162175583928962571846018676395742098636925220489501953125 kDa
0.0000000000000000000000000000000000000235098870164457501595930500960810877919644812859230093381978710493184626102447509765625 kDa
0.00000000000000000000000000000000000001175494350822287507979652504804054389598224064296150466909893552465923130512237548828125 kDa
0.000000000000000000000000000000000000005877471754111437539898262524020271947991120321480752334549467762329615652561187744140625 kDa
0.0000000000000000000000000000000000000029387358770557187699491312620101359739955601607403761672747338811648078262805938720703125 kDa
0.00000000000000000000000000000000000000146936793852785937849746563100506798699778008037018808363736694058240391314029693603515625 kDa
0.000000000000000000000000000000000000000734683969263929689248732815502533993498890040185094041818683470291201956570148468017578125 kDa
0.0000000000000000000000000000000000000003673419846319648446243664077512669967494450200925470209093417351456009782850742340087890625 kDa
0.00000000000000000000000000000000000000018367099231598242231218320387563349837472251004627351045467086757280048914253711700439453125 kDa
0.0091835496157991211156091601937781749187236255002313755227335433786400244571268558502197265625 kDa
0.00459177480789956055780458009688908745936181275011568776136677168932001222856342792510986328125 kDa
0.002295887403949780278902290048444543729680906375057843880683385844660006114281713962554931640625 kDa
0.0011479437019748901394511450242222718648404531875289219403416929223300030571408569812774658203125 kDa
0.00057397185098744506972557251211113593242022659376446097017084646116500152857042849061373291015625 kDa
0.000286985925493722534862786256055567966210113296882230485085423230582500764285214245306866455078125 kDa
0.0001434929627468612674313931280277839831050566484411152425427116152912503821426071226534332275390625 kDa
0.007174648137343063371569656401389199155250282422055762127135580764562519107130356132671661376953125 kDa
0.0035873240686715316857848282006945995776251412110278810635677903822812559535651780663358306884765625 kDa
0.00179366203433576584289241410034729978881257060551394053178389519114062777678258903316791534423828125 kDa
0.0008968310171678829214462070501736498944062853027569702658919475955720313888912945165839576722119140625 kDa
0.00044841550858394146072310352508682494720314265137848513294597379778601569444564725829197883610595703125 kDa
0.000224207754291970730361551762543412473601571325689242566472986898893007847222823629145989418052978515625 kDa
0.0001121038771459853651807758812717062368007856628446212832364934494465039236114118145729947090264892578125 kDa
0.005605193857299268259038794063585311840039283142231064161824672472325196180570559072899735451324462890625 kDa
0.0028025969286496341295193970317926559200196415711155320809123362361625980902852795364498677256622314453125 kDa
0.00140129846432481706475969851589632796000982078555776604045616811808129904514263976822493386283111572265625 kDa
0.000700649232162408532379849257948163980004910392778883020228084059040649522571319884112466

Example 2

Yeast peptides inhibit proteolytic activity of human separase in similar concentration as they inhibit yeast separase and influence the processing of human separase

To further study the mechanism of separase activation it was tested if two different peptide inhibitors developed to inhibit separase from budding yeast (Uhlmann et al., 2000) are able to inhibit the protease activity of human separase. These inhibitors are synthetic peptides containing the cleavage site of budding yeast SCC1, "SVEQGR", where the last arginine residue represents the P1 site after which separase cleaves. The C-terminus of this peptide is either modified to a chloromethyl ketone (cmk) or to an acyloxymethyl ketone (amk). Both peptide derivatives are coupled to biotin moieties at their N-termini. The two inhibitors are therefore called Bio-SVEQGR-cmk and Bio-SVEQGR-amk. When these inhibitors were added to human separase that had been isolated by immunoprecipitation and had been activated in mitotic *Xenopus* extracts as above, it was observed that both inhibitors are able to block the ability of separase to cleave SCC1 (Figure 2A). The concentration of these peptide derivatives required to inhibit human separase was similar to the concentration needed to inhibit separase from budding yeast (compare Fig. 2, upper panel and WO 00/48627, Uhlmann et al., 2000). It was further observed in this experiment that the formation of the p55 cleavage product of human separase was largely inhibited by both peptides at the same concentration at which the ability of separase to cleave SCC1 was inhibited (Figure 2B).

Fig. 2A: The structure of the yeast peptides

Fig. 2B: Separase immunoprecipitates obtained from nocodazole arrested HeLa cells bound by antibodies against the C-terminus of separase coupled to beads were activated in mitotic *Xenopus* egg extracts. Subsequently samples were incubated with indicated concentrations of yeast peptides

(Biotin-SVEQGR-cmk or Biotin-SVEQGR-amk). After a short wash samples were mixed with SCC1-myc reaction mix for 1 hour. Samples were analysed by immunoblotting with antibodies against myc. Cleaved SCC1 is marked by an arrow.

Fig. 2C: The samples (see B) were immunoblotted with antibodies against separase.

Example 3

Human peptides inhibit proteolytic activity of human separase in a similar concentration as the yeast peptides inhibit yeast and human separase

Separase immunoprecipitates obtained from nocodazole-arrested HeLa cells bound by antibodies against the C-terminus of separase coupled to beads were activated in mitotic *Xenopus* egg extracts. Subsequently samples were incubated with the indicated concentrations of human peptides (DREIMR-amk or Biotin-DREIMR-amk). After washing samples were mixed with SCC1-myc reaction mix for 1 hour. Samples were analysed by immunoblotting with antibodies against myc. For control a sample was treated with the same concentration of DMSO which was used for the solubilization of the peptides (DMSO). The SCC1-myc reaction mix was loaded as an input control (SCC1-myc input). It was found that peptide inhibitors developed on the basis of the cleavage recognition site of human SCC1, "DREIMR", were able to inhibit separase at a similar concentration as the peptide inhibitors derived from yeast (Fig. 3).

Fig. 3A shows the structure of the human peptide

Fig. 3B shows that human peptide derivatives inhibit the SCC1 cleavage activity of separase. Full length SCC1 is indicated by an arrowhead, cleaved SCC1 is marked by an arrow.

Example 4

Addition of yeast inhibiting peptides at different stages during the activation of separase suggests that the cleaved forms are the active forms of separase and that securin blocks access of substrates to the active site of separase

To further test which form of separase represents the active protease, the ability of Bio-SVEQGR-amk, the more effective one of the two yeast peptide inhibitors, to bind to different forms of separase, was tested. Previous work has shown that the peptide derivatives inhibit separase by covalently binding to an active site cysteine residue within separase (Uhlmann et al., 2000). These binding reactions can be directly visualized by separating the separase-inhibitor conjugate by SDS gel electrophoresis and by subsequently labeling the biotin moiety on the peptide derivative by streptavidin (Uhlmann et al., 2000). By using this method it was found that Bio-SVEQGR-amk bound exclusively to the cleaved forms of human separase when the peptide derivative was added to separase after its activation in mitotic *Xenopus* extracts (Figure 4B, lane 3i). This treatment inhibited SCC1 cleavage by separase (Figure 4C, lane 3i). This observation shows that the active site of separase is accessible to Bio-SVEQGR-amk in the cleaved, but not in the residual amount of full-length separase, confirming the conclusion from the securin addback experiments that the cleaved forms of separase represent active forms of the protease.

When Bio-SVEQGR-amk was added to human separase immunoprecipitates before separase had been activated in mitotic *Xenopus* extracts, only the small amount of p60 that is already present in these immunoprecipitates was labeled by the peptides, whereas full-length separase was not (Figure 4B, lane 1i), further confirming that the active site of separase is only accessible in the cleaved forms. When the peptide inhibitor was washed away before the separase was subsequently incubated in mitotic *Xenopus* extracts separase could be activated normally to cleave SCC1 (Figure 4C, lane 1i). This result suggests that the presence of securin prevents the binding of Bio-SVEQGR-amk to the active site of

separase, implying that securin inhibits separase by directly or indirectly blocking the access of substrates to the active site of separase.

When the activation of human separase immunoprecipitates in mitotic *Xenopus* extracts was carried out in the presence of Bio-SVEQGR-amk both the cleaved forms of separase and full-length separase were covalently labeled with the peptide (Figure 4B, lane 2i) and separase was unable to cleave SCC1 (Figure 4C, lane 2i). This observation suggests that the full-length form of separase is also transiently active, presumably once its bound inhibitor securin has been destroyed, but that this form is normally labile because it is further processed into the cleaved forms by autocleavage. It was further shown that binding of recombinant securin to cleaved active separase prevented the binding of peptide inhibitors to the active site of separase (Fig. 4D). This result suggests that securin inhibits separase by either directly or indirectly blocking the access of substrates to the active site of separase.

Fig. 4A: Separase immunoprecipitates (separase IP) obtained from Nocodazole arrested HeLa cells bound by antibodies against the C-terminus of separase coupled to beads were activated in mitotic *Xenopus* egg extracts (separase IP^{mitotic}). Aliquots were analysed by immunoblotting with antibodies against separase and securin.

Fig. 4B: Separase IPs (see A) were either preincubated with Biotin-SVEQGR-amk (preinc. with inh. peptide) or with DMSO (preinc. with DMSO), subsequently washed and aliquots were taken. Thereafter they were incubated in mitotic *Xenopus* egg extracts and washed again. Samples were taken for analysis (1i, 1c). Separase IPs were activated either in mitotic *Xenopus* egg extracts which were driven into mitosis in the presence of Biotin-SVEQGR-amk or DMSO, subsequently washed and aliquots were taken for analysis (2i, 2c). Already mitotically activated separase IPs (see A) were incubated with Biotin-SVEQGR-amk or DMSO,

thereafter washed and aliquots were taken for analysis (3i, 3c). All samples were analysed by immunoblotting with avidin.

Fig. 4C: Samples 1i, 1c, 2i, 2c, 3i and 3c (see B) were mixed with SCC1-myc reaction mix for 1 hour and analysed by immunoblotting with antibodies against myc. Arrows indicate the first and second SCC1 cleavage product.

Fig. 4D: Activated separase immunoprecipitates bound by antibodies against the C-terminus of separase to beads were first incubated with recombinant securin or, for control, with recombinant truncated cyclinB. After washing the precipitates were incubated with the human peptide inhibitor. Thereafter, the immunoprecipitates were again washed and analyzed by immunoblotting.

Example 5

a) Cloning of full length human separase

The missing N-terminal part of human separase was amplified from a HeLa cDNA library by polymerase chain reaction using the following primers:

5'primer: 5'GGCCAATTGATATCATGAGGAGCTTCAAAAGAG3' (SEQ ID NO:3)

3'primer: 5'CAACTGTCCACTAGTTGGGTCAGG3' (SEQ ID NO:4)

The resulting DNA fragment was inserted via EcoRV and SpeI into the existing truncated form of human separase (KIAA 0165). The complete coding sequence of human separase is shown in SEQ ID NO: 1, the amino acid sequence is shown in SEQ ID NO:2.

b) Preparation of recombinant human separase

Human separase was N-terminally tagged with a Flag epitope and transiently transfected in HeLa cells either in a single transfection or in a cotransfection with human securin which was C-terminally tagged with a myc epitope. For control HeLa cells were also transiently transfected with securin-myc. After 24 hours transfection 330 nM nocodazole was added for 18 hours. Cells were harvested, washed with PBS and cell extracts were generated as described in Waizenegger et al. 2000. These cell extracts were used to immunoprecipitate exogenous Flag-separase with mouse anti-Flag antibodies bound to sepharose. These immunoprecipitates were then incubated in mitotic *Xenopus* egg extracts and reisolated. The immunoprecipitates and the mitotically activated immunoprecipitates were analysed by immunoblotting with mouse antibodies against separase (7A6), securin (mouse serum) and Flag (M2, Stratagene). The mitotically activated immunoprecipitates were analysed for their activity (see above: SCC1 in vitro cleavage assay).

Example 6

Mitotically activated separase has autocatalytic activity

To test if separase has autocatalytic activity, a myc-tagged form of separase obtained by in vitro transcription and translation was used as a substrate. The transcription-translation reaction was carried out in the presence of ^{35}S -labeled methionine and cysteine, resulting in radiolabeled translation products. The in vitro translated separase was stable when incubated with separase immunoprecipitates which were incubated in interphase *Xenopus* egg extracts but in vitro translated separase was cleaved when it was incubated with active separase obtained by incubation of separase immunoprecipitates in mitotic *Xenopus* egg extracts (Figure 5). These results show that separase cleavage can occur autocatalytically in

trans. This allows to distinguish between separase acting as an enzyme and separase serving as a substrate.

Figure 5 shows that only upon mitotic activation of separase separase-myc is autocatalytically cleaved.

Fig. 5A: Separase immunoprecipitates (separase IP) obtained from Nocodazole arrested HeLa cells bound by antibodies against the C-terminus of separase coupled to beads were either incubated in mitotic (separase IP^{mitotic}) or in interphase *Xenopus* egg extracts (separase IP^{interphase}). Aliquots were analysed by immunoblotting with antibodies against separase and securin.

Fig. 5B: Separase immunoprecipitates were incubated either in a mitotic or interphase *Xenopus* egg extracts and then mixed with recombinant separase-myc reaction mix. At indicated time points samples were taken and analysed by immunoblotting with antibodies against myc.

Example 7

N- and C-terminally cleavage products of separase remain physically associated and tagged recombinant human separase is active

To test if the N- and C-terminal fragments of separase remain non-covalently associated after cleavage, tagged forms of separase were generated.

N-terminally FLAG-tagged full length separase was transiently expressed in HeLa cells as described in Example 5B and isolated by immunoprecipitation with an anti-FLAG antibody. The immunoprecipitates were incubated in mitotic *Xenopus* egg extracts to allow securin destruction and separase cleavage (Figure 6A). After re-isolation the immunoprecipitates were immunoblotted with anti-separase antibodies, anti-securin antibodies or anti-FLAG antibodies. Both C- and N-terminal separase fragments could be detected in the immunoprecipitates,

suggesting that the N- and C-terminal separase fragments remain associated after cleavage (Figure 6A).

Fig. 6A: HeLa cells were transiently transfected with FLAG-separase, FLAG-separase and securin-myc or only with securin-myc. Mitotic extracts were performed from these cells and used for immunoprecipitation with anti-FLAG antibodies bound to sepharose (IP). The immunoprecipitates were activated in mitotic *Xenopus* egg extracts (IP^m). The immunoprecipitates were analysed by immunoblotting with antibodies against securin, separase (7A6) and FLAG.

Fig. 6B: Aliquots of above described immunoprecipitates were incubated with SCC1-myc reaction mix. At indicated time points samples were withdrawn and analysed by immunoblotting with antibodies against myc. Arrows indicate SCC1-myc cleavage products.



Example 8

Mapping of the separase recognition sites

The cleavage sites in human separase were mapped by a method that has been previously used to map cleavage sites in SCC1 (WO00/48627). Briefly, truncated versions of the human separase cDNA were generated by polymerase chain reactions, and the resulting cDNAs were used directly for coupled in vitro transcription-translation reactions by using rabbit reticulocyte lysates. The transcription-translation reactions were carried out in the presence of ^{35}S -labeled methionine and cysteine, resulting in radiolabeled translation products. These were then separated by SDS gel electrophoresis side by side with the in vitro cleavage products of mitotically activated human separase immunoprecipitates which were detected by immunoblotting. The comparison of the electrophoretic mobility of a series of deletion mutants with the mobility of the in vitro cleavage products narrows down the regions of cleavage to about 10 amino acid residues. Because separase cleavage sites in all known organisms cleave after the sequence EXXR (where X represents any amino acid residue; WO 00/48627 ; Uhlmann et al., 1999; Buonomo et al., 2000; Hauf et al., 2001) it is assumed that SFEILR¹⁵⁰⁸ and EWELLR¹⁵³⁵ represent two of the separase cleavage sites.

N-terminally truncated separase cDNA was generated by polymerase chain reaction. The 5'primers contain a sequence with the T7 polymerase binding site

1. start aa 1487

5'GAATTCTAATACGACTCACTATAGGATCCATGATCCCTGAGGAAGAAC
TGACTG^{3'} (SEQ ID NO:5)

2. start aa 1507

5'GAATTCTAATACGACTCACTATAGGATCCATGTCTGACGGGGAAGAC
TCAGCCTC³ (SEQ ID NO:6)

3. start aa 1536

5'GAATTCTAATACGACTCACTATAGGATCCATGGATTCCAGCAAGAAGA
AGCTGCCC³ (SEQ ID NO:7)

The following 3'primer was used:

5'TTATTACCGCAGAGAGACAGGCAAGCC³ (SEQ ID NO:8)

The PCR products were in vitro transcribed and translated with the TNT system (Promega). The recombinant products, which start with an exogenous methionine at the indicated amino acids obtained, were loaded side by side with in vitro cleaved separase on a SDS-PAGE. For immunoblotting the mouse anti-separase antibody (7A6) was used. The results are shown in Fig. 8.

Example 9

Assay for identifying separase inhibitors using a fluorogenic peptid substrate

In order to establish a robust screening assay (based on liquid phase fluorescence energy transfer) for identifying inhibitors of recombinant human separase, four peptide substrates (1: SFEILR-AMC, 2: SFEILRG-AMC, 3:EWELLR-AMC and 4: DREIMR-AMC) were synthesized. These peptides are linked to AMC (7-Amido-4-methylcoumarin), a fluorogenic group, which has been described for proteolytic assays, such as for trypsin (Zimmerman et al., 1977) and cathepsin B (Barrett and Kirschke, 1981). AMC serves as a donor fluorophore and in the case of the separase-

specific peptide substrates the amino acid bonds of the peptides function as acceptor chromophores (Fig. 9A). The peptide substrates are cleaved at the P1'-AMC junction; by processing the peptide-AMC bond the unquenched AMC is set free and can be monitored as increasing fluorescence. The designed peptide substrates represent the intramolecular cis-cleavage site in separase itself (peptides 1 - 3) and the intermolecular trans-cleavage site in cohesin respectively (peptide 4). Since all these peptides contain an Arg at the P1' site, the peptides could be easily tested by utilizing trypsin (specific recognition site at P1': Arg or Lys). Except for peptide 2, which contains an additional Gly between P1' (Arg) and the AMC residue, all peptide substrates could be efficiently cleaved (Fig. 9B) by trypsin as follows:

Trypsin solution (Gibco 043-90317 FU) was diluted 1:1000 in Hepes buffer containing 20mM Hepes (pH: 7.7), 100mM KCl, 1mM MgCl₂, 0.1mM CaCl₂ and 1mM DTT (freshly added). 1 µl of peptide 1 (4mg/ml in DMSO) was added, mixed and measured in a Hitachi f-2000 fluorescence spectrophotometer (Ex: 355 and Em: 460nm). A typical kinetics is shown in Fig. 9B.

Due to the complex activation procedure of recombinant human separase, a bead-suspension with coupled and activated separase had to be used for the establishment of a separase assay (activation of separase is described in Materials and Methods). The separase assay was performed as follows: ~ 500 µl of separase bead suspension was diluted with 1800 µl Hepes buffer. 30 µl of the diluted suspension was applied per well of a 96 "Packard OptiPlate black" plate. Additionally, 70 µl Hepes buffer and 1 µl of a LMW-compound stock solution (5mg/ml in DMSO) were added per well. After 10 minutes of pre-incubation at room temperature the reaction was initialized by adding 1 µl of the peptide 1 (4mg/ml in DMSO). The reaction was monitored in a Fluoroskan II 96-well reader (Ex: 355nm, Em: 460nm) at room temperature (Fig. 10). As a control, measurement was performed in the presence of 2 µl DMSO per 100 µl reaction volume whereas for

inhibition a cleavage peptide linked to an AMK (acyl-oxymethyl ketone) residue, which was described in WO 00/48627, was used. The AMK residue serves as a broad-spectrum inhibitor for many cysteine and serine proteases (for details see Beynon and Bond, 1989). In parallel the activity of the separase preparations bound to the beads was tested in an in vitro assay demonstrating the cleavage of cohesin (for details see Example 2, 3, Fig. 10). From a compound pool, 51 compounds that were shown to be potential protease inhibitors in preliminary experiments, were selected and tested for their ability to interfere with the activity of human separase. Out of these compounds, nine were found to inhibit separase activity within the same range as the AMK peptide (Fig. 11).

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
22

References

- Ambrose WP, et al., (1998), *Anal Biochem*, Oct 15, 263(2): 150-7
- Barrett and Kirschke, 1981, *Meth. Enzymol.* 80, 535
- Beynon and Bond, "Proteolytic Enzymes, a Practical Approach", IRL Press 1989
- Brown AM, et al., (1994), *Anal Biochem*, Feb 15, 217(1): 139-47
- Buonomo SB, Clyne RK, Fuchs J, Loidl J, Uhlmann F, Nasmyth K; Cell 2000 Oct 27;103(3):387-98
- Corretani M, et al., (1999), *Anal Biochem*, Jan 15, 266(2): 192-7
- Ciosk R, Zachariae W, Michaelis C, Shevchenko A, Mann M, Nasmyth K; Cell 1998 Jun 12;93(6):1067-76
- Elbashir et al., (2001) *Nature* 411(6836):494-8.
- Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y; EMBO J 1997 May 1;16(9):2271-81
- Gershkovich, A.A. and Kholodovych, V.V. (1996), *J Biochem Biophys Meth* 33, 135
- Gmachl M, Gieffers C, Podtelejnikov AV, Mann M, Peters JM; Proc Natl Acad Sci U S A 2000 Aug 1;97(16):8973-8
- Gray NM, et al., (1994), *Anal Biochem*, 216(1): 89-96
- Hauf S., Waizenegger IC, Peters JM; Science 2001 August 17; 293: 1320-1323
- Jolley, M.E. (1996), *J Biomol Screening* 1, 33

- Lee IA, Seong C, Choe IS; *Biochem Mol Biol Int* 1999 May;47(5):891-7
- Levine LM, et al., (1997), *Anal Biochem*, Apr 5, 247(1): 83-8
- Matayoshi, E.D. (1990), *Science* 247, 954
- Murray MG, et al., (1993), *Gene*, Nov 30, 134(1):123-8
- Nasmyth K, Peters JM, Uhlmann F; *Science* 2000 May 26;288(5470):1379-85
- Remington's Pharmaceutical Sciences, 1980, Mack Publ. Co. Easton, PA, Osol (ed.)
- Sarubbi E, et al., (1991), *FEBS Lett*, Feb 25, 279(2): 265-9
- Singh J, et al., (1996), *Bioorg Med Chem*, 4(5): 639-43
- Stebbins J. and Debouck C., (1997), *Anal Biochem*, Jun 1, 248(2): 246-50
- Taliani M, et al., (1996), *Anal Biochem*, Aug 15, 240(1):60-7
- Uhlmann F, Wernic D, Poupart MA, Koonin EV, Nasmyth K; *Cell* 2000 Oct 27;103(3):375-86
- Uhlmann F, Lottspeich F, Nasmyth K; *Nature* 1999 Jul 1;400(6739):37-42
- Waizenegger IC, Hauf S, Meinke A, Peters; *JM Cell* 2000 Oct 27;103(3): 399-410
- Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S; *J Clin Endocrinol Metab* 1999 Feb;84(2):761-7
- Zimmerman et al., 1977, *Anal. Biochem.* 78, 47